The 2026 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Michael Ong discussing TRIPLE-SWITCH (SWOG/CCTG-PR26), a randomized phase III clinical ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Genomic alterations and pathologic responses to neoadjuvant androgen receptor pathway inhibitor (ARPI) doublets vs docetaxel triplets in the Genomic Umbrella Neoadjuvant study (GUNS). This is an ASCO ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...